Proton NMR chemical shifts and coupling constants for brain metabolites

NMR in Biomedicine

Volumn 13, Issue 3, 2000, Pages 129-153

  Govindaraju, Varanavasi ^a   Young, Karl ^a   Maudsley, Andrew A ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Brain metabolites; Chemical shifts; Coupling constants; In vivo; Nuclear magnetic resonance spectroscopy; Parametric spectral analysis; Proton; Review

Indexed keywords

4 AMINOBUTYRIC ACID; ACETIC ACID; ADENOSINE TRIPHOSPHATE; ALANINE; ASPARTIC ACID; CHOLINE; CREATINE; CREATINE PHOSPHATE; ETHANOLAMINE; GLUCOSE; GLUTAMIC ACID; GLUTAMINE; GLUTATHIONE PEROXIDASE; GLYCEROL; GLYCEROPHOSPHORYLCHOLINE; GLYCINE; HISTAMINE; HISTIDINE; HOMOCARNOSINE; INOSITOL; LACTIC ACID; N ACETYLASPARTIC ACID; N ACETYLASPARTYLGLUTAMIC ACID; PHENYLALANINE; PHOSPHOETHANOLAMINE; PHOSPHORYLCHOLINE; PYRUVIC ACID; SERINE; SUCCINIC ACID; TAURINE; THREONINE; TRYPTOPHAN; TYROSINE; VALINE;

ACCURACY; ANALYTIC METHOD; ANIMAL TISSUE; ARTICLE; BRAIN; COMPUTER SIMULATION; MALE; NONHUMAN; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; RAT; SPECTRAL SENSITIVITY; SPECTROSCOPY;

ACETIC ACID; ANIMALS; ASPARTIC ACID; BRAIN; BRAIN CHEMISTRY; MAGNETIC RESONANCE SPECTROSCOPY; PROTONS; RATS;

MAMMALIA;

EID: 0034099574     PISSN: 09523480     EISSN: None     Source Type: Journal    
DOI: 10.1002/1099-1492(200005)13:3<129::AID-NBM619>3.0.CO;2-V     Document Type: Article

References (163)

1. De Graaf AA, Bovee WMMJ. Improved quantification of in vivo 1H NMR spectra by optimization of signal acquisition and processing and by incorporation of prior knowledge into the spectral fitting. Magn. Reson. Med. 1990; 15: 305-319.
2. Provencher SW, Estimation of metabolite concentrations from localized in vivo proton NMR spectra. Magn. Reson. Med. 1993; 30: 672-679.
3. Slotboom J, Boesch C, Kreis R. Versatile frequency domain fitting using time domain models and prior knowledge. Magn. Reson. Med. 1998; 39: 899-911.
4. Young K, Govindaraju V, Sober BJ, Maudsley AA. Automated spectral analysis I: formation of a priori information by spectral simulation. Magn. Reson. Med. 1998; 40: 812-815.
5. Sober BJ, Young K, Govindaraju V, Maudsley AA. Automated spectral analysis III: Application to in vivo proton MR spectroscopy and spectroscopic imaging. Magn. Reson. Med. 1998; 40: 822-831.
6. Behar KL, den Hollander JA, Stromski ME, Ogino T, Shulman RG, Petroff OA, Prichard JW. High-resolution 1H nuclear magnetic resonance study of cerebral hypoxia in vivo. Proc. Natl Acad. Sci. USA 1983; 80: 4945-4948.
7. 1H NMR of intact tissues at 11.1 T. J. Magn. Reson. 1984; 57: 519-525.
8. Arús C, Chang Y-C, Bárány M. Proton nuclear magnetic resonance spectra of excised rat brain. Assignment of resonances. Physiol. Chem. Phys. Med. NMR 1985; 17: 23-33.
9. Cerdán S, Parrilla R, Santoro J, Rico M. 1H NMR detection of cerebral myo-inositol. FEBS Lett. 1985; 187: 167-172.
10. Fan TW, Higashi RM, Lane AN, Jardetzky O. Combined use of 1H-NMR and GC-MS for metabolite monitoring and in vivo 1H-NMR assignments. Biochim. Biophys. Acta 1986; 882: 154-167.
11. Sze DY, Jardetzky O. Determination of metabolite and nucleotide concentrations in proliferating lymphocytes by 1H-NMR of acid extracts. Biochim. Biophys. Acta 1990; 1054: 181-197.
12. Michaelis T, Merboldt KD, Hänicke W, Gyngell ML. Bruhn H, Frahm J. On the identification of cerebral metabolites in localized 1H NMR spectra of human brain in vivo. NMR Biomed. 1991; 4: 90-98.
13. Behar KL, Ogino T. Assignment of resonances in the 1H spectrum of rat brain by two-dimensional shift correlated and J-resolved NMR spectroscopy. Magn. Reson. Med. 1991; 17: 285-303.
14. van Zijl PCM, Moonen CTW. In situ changes in purine nucleotide and N-acetyl concentrations upon inducing global ischemia in cat brain. Magn. Reson. Med. 1993; 29: 381-385.
15. Ryner LN, Sorenson JA, Thomas MA. Localized 2D J-resolved 1H MR spectroscopy: strong coupling effects in vitro and in vivo. [Published erratum appears in Magn. Reson. Imag. 1995; 13: 1043]. Magn. Reson. Imag. 1995; 13: 853-869.
16. Smart SC, Fox GB, Allen KL, Swanson AG, Newman MJ, Swayne GT, Clark JB, Sales KD, Williams SC. Identification of ethanolamine in rat and gerbil brain tissue extracts by NMR spectroscopy. NMR Biomed. 1994; 7: 356-365.
17. Wevers RA, Engelke U, Heerschap A. High-resolution 1H-NMR spectroscopy of blood plasma for metabolic studies. [See comments.] Clin. Chem. 1994; 40: 1245-1250.
18. Wevers RA, Engelke U, Wendel U, de Jong JG, Gabreëls FJ, Heerschap A. Standardized method for high-resolution 1H-NMR of cerebrospinal fluid. Clin. Chem. 1995; 41: 744-751.
19. Slotboom J, Mehlkopf AF, Bovee WMMJ. The effects of frequency-selective RF pulses on J-coupled spin-1/2 systems. J. Magn. Reson. Ser. A 1994; 108: 38-50.
20. Yablonskiy DA, Neil JJ, Raichle ME, Ackerman JJ. Homonuclear J coupling effects in volume localized NMR spectroscopy: pitfalls and solutions. Magn. Reson. Med. 1998; 39: 169-178.
21. Behar KL, Rothman DL, Spencer DD, Petroff OAC. Analysis of macromolecule resonances in 1H NMR spectra of human brain. Magn. Reson. Med. 1994; 32: 294-302.
22. Young K, Soher BJ, Maudsley AA. Automated spectral analysis II: application of wavelet shrinkage for characterization of nonparameterized signals. Magn. Reson. Med. 1998; 40: 816-821.
23. Govindaraju V, Basus VJ, Matson GB, Maudsley AA. Measurement of chemical shifts and coupling constants for glutamate and glutamine. Magn. Reson. Med. 1998; 39: 1011-1013.
24. Govindaraju V, Young K, Matson GB, Maudsley AA. Optimization of acquisition sequence parameters by spectral simulation (submitted).
25. Rigaudy J, Klesney SP, eds. Nomenclature of Organic Chemistry, Pergamon Press, Oxford (1979).
26. Wüthrich K, NMR of Proteins and Nucleic Acids, Wiley, New York (1986).
27. Wishart DS, Bigam CG, Yao J, Abildgaard F, Dyson HJ, Oldfield E, Markley JL, Sykes BD. 1H, 13C and 15N chemical shift referencing in biomolecular NMR. J. Biomol. NMR 1995; 6: 135-140.
28. Smith SA, Levante TO, Meier BH, Ernst RR. Computer simulations in magnetic resonance. An object-oriented programming approach. J. Magn. Reson. Ser. A 1994; 106: 75-105.
29. Serkova N, Brand A, Christians U, Leibfritz D. Evaluation of the effects of immunosuppressants on neuronal and glial cells in vitro by multinuclear magnetic resonance spectroscopy. Biochim. Biophys. Acta 1996; 1314: 93-104.
30. Middlehurst CR, King GF, Beilharz GR, Hunt GE, Johnson GFS, Kuchel PW. Studies of rat brain metabolism using proton nuclear magnetic resonance: spectral assignments and monitoring of prolidase, acetylcholinesterase and glutaminase. J. Neurochem. 1984; 43: 1561-1567.
31. Petroff OAC, Spencer DD, Alger JR, Prichard JW. High-field proton magnetic resonance spectroscopy of human cerebrum obtained during surgery for epilepsy. Neurology 1989; 39: 1197-1202.
32. Urenjak J, Williams SR, Gadian DG, Noble M. Proton nuclear magnetic resonance spectroscopy unambiguously identifies different neural cell types. J. Neurosci. 1993; 13: 981-989.
33. Martin M, Merle M, Labouesse J, Canioni P. Postnatal decrease of acetate concentration in rat cerebellum. J. Neurosci. Res. 1994; 37: 103-107.
34. Florian CL, Preece NE, Bhakoo KK, Williams SR, Noble M. Characteristic metabolic profiles revealed by 1H NMR spectroscopy for three types of human brain and nervous system tumours. NMR Biomed. 1995; 8: 253-264.
35. Peeling J, Wong D, Sutherland GR. Nuclear magnetic resonance study of regional metabolism after forebrain ischemia in rats. Stroke 1989; 20: 633-640.
36. Kim SH, Chang KH, Song IC, Han MH, Kim HC, Kang HS, Han MC. Brain abscess and brain tumor: discrimination with in vivo H-1 MR spectroscopy. Radiology 1997; 204: 239-245.
37. Davies SE, Newcombe J, Williams SR, McDonald WI, Clark JB. High resolution proton NMR spectroscopy of multiple sclerosis lesions. J. Neurochem. 1995; 64: 742-748.
38. Martin M, Labouesse J, Canioni P, Merle M. N-Acetyl-L-aspartate and acetate 1H NMR signal overlapping under mild acidic pH conditions. Magn. Reson. Med. 1993; 29: 692-694.
39. Birken DL, Oldendorf WH. N-Acetyl-L-aspartic acid: a literature review of a compound prominent in 1H-NMR spectroscopic studies of brain. Neurosci. Biobehav. Rev. 1989; 13: 23-31.
40. Miyake M, Kakimoto Y, Sorimachi M. A gas chromatographic method for the determination of N-acetyl-L-aspartic acid, N-acetyl-alpha-aspartylglutamic acid and beta-citryl-L-glutamic acid and their distributions in the brain and other organs of various species of animals. J. Neurochem. 1981; 36: 804-810.
41. Baslow MH. A review of phylogenetic and metabolic relationships between the acylamino acids, N-acetyl-L-aspartic acid and N-acetyl-L-histidine, in the vertebrate nervous system. J. Neurochem. 1997; 68: 1335-1344.
42. Tsai G, Coyle JT. N-Acetylaspartate in neuropsychiatric disorders. Prog. Neurobiol. 1995; 46: 531-540.
43. Rudkin TM, Arnold DL. Proton magnetic resonance spectroscopy for the diagnosis and management of cerebral disorders. Arch. Neurol. 1999; 56: 919-926.
44. Simmons ML, Frondoza CG, Coyle JT. Immunocytochemical localization of N-acetyl-aspartate with monoclonal antibodies. Neuroscience 1991; 45: 37-45.
45. Urenjak J, Williams SR, Gadian DG. Noble M. Specific expression of N-acetylaspartate in neurons, oligodendrocyte-type-2 astrocyte progenitors, and immature oligodendrocytes in vitro. J. Neurochem. 1992; 59: 55-61.
46. Brulatout S, Méric P, Loubinoux I, Borredon J, Corrèze JL, Roucher P, Gillet B, Bérenger G, Beloeil JC, Tiffon B, Mispelter J, Seylaz J. A one-dimensional (proton and phosphorus) and two-dimensional (proton) in vivo NMA spectroscopic study of reversible global cerebral ischemia. J Neurochem. 1996; 66: 2491-2499.
47. De Stefano N, Matthews PM, Arnold DL. Reversible decreases in N-acetylaspartate after acute brain injury. Magn. Reson. Med. 1995; 34: 721-727.
48. Wittsack HJ, Kugel H, Roth B, Heindel W. Quantitative measurements with localized 1H MR spectroscopy in children with Canavan's disease. J. Magn. Reson. Imag. 1996; 6: 889-893.
49. 1H NMR of brain slices. J. Magn. Reson. 1985; 63: 376-379.
50. Kreis R. Quantitative localized 1H MR spectroscopy for clinical use. Prog. Magn. Reson. Spectrosp. 1997; 31: 155-195.
51. Pouwels PJ, Frahm J. Regional metabolite concentrations in human brain as determined by quantitative localized proton MRS. Magn. Reson. Med. 1998; 39: 53-60.
52. Wang Y, Li SJ. Differentiation of metabolic concentrations between gray matter and white matter of human brain by in vivo 1H magnetic resonance spectroscopy Magn. Reson. Med. 1998; 39: 28-33.
53. Lim KO, Spielman DM. Estimating NAA in cortical gray matter with applications for measuring changes due to aging. Magn. Reson. Med. 1997; 37: 372-377.
54. Saunders DE, Howe FA, van den Boogaart A, Griffiths JR, Brown MM. Aging of the adult human brain: In vivo quantitation of metabolite content with proton magnetic resonance spectroscopy. J. Magn. Reson. Imaging 1999; 9: 711-716.
55. Curatolo A, d'Arcangelo P, Lino A, Brancati A. Distribution of N-acetyl-aspartic and N-acetyl-aspartyl-glutamic acids in nerve tissue. J. Neurochem. 1965; 12: 339-342.
56. Ory-Lavollée L, Blakely RD, Coyle JT. Neurochemical and immunocytochemical studies on the distribution of N-acetyl-aspartylglutamate and N-acetyl-aspartate in rat spinal cord and some peripheral nervous tissues. J. Neurochem. 1987; 48: 895-899.
57. d'Arcangelo P, Brancati A. Distribution of N-acetylaspartate, N-acetylaspartylglutamate, free glutamate and aspartate following complete mesencephalic transection in rat neuraxis. Neurosci. Lett. 1990; 114; 82-88.
58. Koller KJ, Zaczek R, Coyle JT. N-Acetyl-aspartyl-glutamate: regional levels in rat brain and the effects of brain lesions as determined by a new HPLC method. J. Neurochem. 1984; 43: 1136-1142.
59. Pouwels PJ, Frahm J. Differential distribution of NAA and NAAG in human brain as determined by quantitative localized proton MRS. NMR Biomed. 1997; 10: 73-78.
60. Coyle JT. The nagging question of the function of N-acetylaspartylglutamate. Neurobiol. Dis. 1997; 4: 231-238.
61. Passani LA, Vonsattel JP, Carter RE, Coyle JT. N-Acetylaspartylglutamate, N-acetylaspartate, and N-acetylated alpha-linked acidic dipeptidase in human brain and their alterations in Huntington and Alzheimer's diseases. Mol. Chem. Neuropathol. 1997; 31: 97-118.
62. Holowenko D, Peeling J, Sutherland G. 1H NMR properties of N-acetylaspartylglutamate in extracts of nervous tissue of the rat. NMR Biomed. 1992; 5: 43-47.
63. Erecianska M, Silver IA. ATP and brain function. J. Cereb. Blood Flow Metab. 1989; 9: 2-19.
64. Son TD, Chachaty C. Proton NMR and spin lattice relaxation study of nucleoside di-and triphosphates in neutral aqueous solutions. Biochim. Biophys. Acta 1977; 500: 405-418.
65. Poptani H, Gupta RK, Jain VK, Roy R, Pandey R. Cystic intracranial mass lesions: possible role of in vivo MR spectroscopy in its differential diagnosis. Magn. Reson. Imag. 1995; 13: 1019-1029.
66. Higuchi T, Graham SH, Fernandez EJ, Rooney WD, Gaspary HL, Weiner MW, Maudsley AA. Effects of severe global ischemia on N-acetylaspartate and other metabolites in the rat brain. Magn. Reson. Med. 1997; 37: 851-857.
67. Rothman DL, Behar KL, Hetherington HP, Shulman RG. Homonuclear 1H double resonance difference spectroscopy of the rat brain in vivo. Proc. Natl Acad. Sci. USA 1984; 81: 6330-6334.
68. Petroff OA, Rothman DL. Measuring human brain GABA in vivo: effects of GABA-transaminase inhibition with vigabatrin. Mol. Neurobiol. 1998; 16: 97-121.
69. Rothman DL, Petroff OA, Behar KL, Mattson RH. Localized 1H NMR measurements of gamma-aminobutyric acid in human brain in vivo. Proc. Natl Acad. Sci. USA 1993; 90: 5662-5666.
70. Wilman AH, Allen PS. Yield enhancement of a double-quantum filter sequence designed for the edited detection of GABA. J. Magn. Reson. Ser. B 1995; 109: 169-174.
71. Keltner Wald LL, Frederick BD, Renshaw PF. In vivo detection of GABA in human brain using a localized double-quantum filter technique. Magn. Reson. Med. 1997; 37: 366-371.
72. Klunk WE, Xu C, Panchalingam K, McClure RJ, Pettegrew JW. Quantitative 1H and 31P MRS of PCA extracts of postmortem Alzheimer's disease brain. Neurobiol. Aging 1996; 17: 349-357.
73. Miller BL. A review of chemical issues in 1H NMR spectroscopy: N-Acetyl-L-aspartate, creatine and choline. NMR Biomed. 1991; 4: 47-52.
74. Tan J, Blüml S, Hoang T, Dubowitz D, Mevenkamp G, Ross B. Lack of effect of oral choline supplement on the concentrations of choline metabolites in human brain. Magn. Reson. Med. 1998; 39: 1005-1010.
75. Miller BL, Chang L, Booth R, Ernst T, Cornford M, Nikas D, McBride D, Jenden DJ. In vivo 1H MRS choline: correlation with in vitro chemistry/histology. Life Sci. 1996; 58: 1929-1935.
76. Michaelis T, Merboldt KJD, Bruhn H, Hänicke W, Frahm J. Absolute concentrations of metabolites in the adult human brain in vivo: quantification of localized proton MR spectra. Radiology 1993; 187: 219-227.
77. Blüml S, Seymour KL, Ross B. Developmental changes in choline- and ethanolimine-containing compounds measured with proton-decoupled 31P MPLS in in vivo human brain. Magn. Reson. Med. 1999; 42: 643-654.
78. Barker PB, Breiter SN, Soher BJ, Chathamn JC, Forder JR, Samphilipo MA, Magee CA, Anderson JA. Quantitative proton spectroscopy of canine brain: in vivo and in vitro correlations. Magn. Reson. Med. 1994; 32: 157-163.
79. Partington P, Feeney J, Burgen AS. The conformation of acetylcholine and related compounds in aqueous solution as studied by nuclear magnetic resonance spectroscopy. Mol. Pharmacol. 1972; 8: 269-277.
80. Blüml S, Zuckerman E, Tan J, Ross BD. Proton-decoupled 31P magnetic resonance spectroscopy reveals osmotic and metabolic disturbances in human hepatic encephalopathy. J. Neurochem. 1998; 71: 1564-1576.
81. Stoll AL, Renshaw PF, De Micheli E, Wurtman R, Pillay SS, Cohen BM. Choline ingestion increases the resonance of choline-containing compounds in human brain: an in vivo proton magnetic resonance study. Biol. Psychiat. 1995; 37: 170-174.
82. Pfeuffer J, Tkác I, Provencher SW, Gruetter R. Toward an in vivo neurochemical profile: quantification of 18 metabolites in short-echo-time 1H NMR spectra of rat brain. J. Magn. Reson. 1999; 141: 104-120.
83. Chang L, Ernst T, Osborn D, Seltzer W, Leonido-Yee M, Poland RE. Proton spectroscopy in myotonic dystrophy: correlations with CTG repeats. [See comments.] Arch. Neurol. 1998; 55: 305-311.
84. Vermathen P, Govindaraju V, Matson GB, Maudsley AA. Detection of downfield 1H resonances in human brain using single voxel and SI methods. Proceedings of the International Society for Magnetic Resonance in Medicine, Abstract, p. 1584. (1999).
85. Ala-Korpela M, Posio P, Mattila S, Korhonen A, Williams SR. Absolute quantification of phospholipid metabolites in brain-tissue extracts by 1H NMR spectroscopy. J. Magn. Reson. Ser. B 1996; 113: 184-189.
86. Lehmann A, Hagberg H, Jacobson I, Hamberger A. Effects of status epilepticus on extracellular amino acids in the hippocampus. Brain Res. 1985; 359: 147-151.
87. Gruetter R, Ugurbil K, Seaquist ER. Steady-state cerebral glucose concentrations and transport in the human brain. J. Neurochem. 1998; 70: 397-408.
88. Gyngell ML, Michaelis T, Hörstermann D, Bruhn H, Hänicke W, Merboldt KD, Frahm J. Cerebral glucose is detectable by localized proton NMR spectroscopy in normal rat brain in vivo. Magn. Reson. Med. 1991; 19: 489-495.
89. Peres M, Bourgeois D, Roussel S, Lefur Y, Devoulon P, Remy C, Barrere B, Decorps M, Pinard E, Riche D, Benabid A-L, Seylaz J. Two-dimensional 1H spectroscopic imaging for evaluating the local metabolic response to focal ischemia in the conscious rat. NMR Biomed. 1992; 5: 11-19.
90. Gruetter R, Garwood M, Ugurbil K, Seaquist ER. Observation of resolved glucose signals in 1H NMR spectra of the human brain at 4 Tesla. Magn. Reson. Med. 1996; 36: 1-6.
91. Merboldt KD, Bruhn H, Hänicke W, Michaelis T, Frahm J. Decrease of glucose in the human visual cortex during photic stimulation. Magn. Reson. Med. 1992; 25: 187-194.
92. Gruetter R, Novotny EJ, Boulware SD, Rothman DL, Shulman RG. 1H NMR studies of glucose transport in the human brain. J. Cereb. Blood Flow Metab. 1996; 16: 427-438.
93. Gurst JE. NMR and the structure of deuterium-glucose. J. Chem. Educ. 1991; 68: 1003-1004.
94. 13C-N.M.R. spectra of D-glucopyranose, 2-acetamido-2-deoxy-D-glucopyranose, and related compounds in aqueous media. Carbohydr. Res. 1977; 59: 19-34.
95. Koch HJ, Perlin AS. Synthesis and 13C N.M.R. spectrum of D-glucose-3-d. Bond polarization differences between the anomers of D-glucose. Carbohydr. Res. 1970; 15: 403-410.
96. Curatolo W, Neuringer LJ, Ruben D, Haberkorn R. Two-dimensional J-resolved 1H-nuclear magnetic resonance spectroscopy of α,β-D-glucose at 500 MHz. Carbohydr. Res. 1983; 112: 297-300.
97. Ross BD. Biochemical considerations in 1H spectroscopy. Glutamate and glutamine; myo-inositol and related metabolites. NMR Biomed. 1991; 4: 59-63.
98. Westergaard N, Sonnewald U, Schousboe A. Metabolic trafficking between neurons and astrocytes: the glutamate/glutamine cycle revisited. Devl. Neurosci. 1995; 17: 203-211.
99. Chamuleau RA, Bosman DK, Bovée WM, Luyten PR, den Hollander JA. What the clinician can learn from MR glutamine/ glutamate assays. NMR Biomed. 1991; 4: 103-108.
100. Pan JW, Mason GF, Pohost GM, Hetherington HP. Spectroscopic imaging of human brain glutamate by water-suppressed J-refocused coherence transfer at 4.1 T. Magn. Reson. Med. 1996; 36: 7-12.
101. Thompson RB, Allen PS. A new multiple quantum filter design procedure for use on strongly coupled spin systems found in vivo: its application to glutamate. Magn. Reson. Med. 1998; 39: 762-771.
102. Prost RW, Mark L, Mewissen M, Li SJ. Detection of glutamate/ glutamine resonances by IH magnetic resonance spectroscopy at 0.5 Tesla. Magn. Reson. Med. 1997; 37: 615-618.
103. Kreis R, Farrow N, Ross BD. Localized 1H NMR spectroscopy in patients with chronic hepatic encephalopathy. Analysis of changes in cerebral glutamine, choline and inositols. NMR Biomed. 1991; 4: 109-116.
104. Kanamori K, Ross BD. In vivo detection of N-15-coupled protons in rat brain by ISIS localization and multiple-quantum editing. J. Magn. Reson. 1999; V139:240-249.
105. Mason GF, Pan JW, Ponder SL, Twieg DB, Pohost GM, Hetherington HP. Detection of brain glutamate and glutamine in spectroscopic images at 4.1 T. Magn. Reson. Med. 1994; 32: 142-145.
106. Gruetter R, Weisdorf SA, Rajanayagan V, Terpstra M, Merkle H, Truwit CL, Garwood M, Nyberg SL, Ugurbil K. Resolution improvements in in vivo 1H NMR spectra with increased magnetic field strength. J Magn. Reson. 1998; 135: 260-264.
107. Meister A, Anderson ME. Glutathione. A. Rev. Biochem. 1983; 52: 711-760.
108. Cooper AJ, Kristal BS. Multiple roles of glutathione in the central nervous system. Biol. Chem. 1997; 378: 793-802.
109. Sian J, Dexter DT, Lees AJ, Daniel S, Agid Y, Javoy-Agid F, Jenner P, Marsden CD. Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia. [See comments.] Ann. Neurol. 1994; 36: 348-355.
110. Brown FF, Campbell ID, Kuchel PW, Rabenstein DC. Human erythrocyte metabolism studies by 1H spin echo NMR. FEBS Lett. 1977; 82: 12-16.
111. Mason RP, Cha GH, Gorrie GH, Babcock EE, Antich PP. Glutathione in whole blood: a novel determination using double quantum coherence transfer proton NMR spectroscopy. FEBS Lett. 1993; 318: 30-34.
112. McKay CN, Brown DH, Reglinski J, Smith WE, Capell HA, Sturrock RD. Changes in glutathione in intact erythrocytes during incubation with penicillamine as detected by 1H spin-echo NMR spectroscopy. Biochim. Biophys. Acta 1986; 888: 30-35.
113. Trabesinger AH, Weber OM, Due CO, Boesiger P. Detection of glutathione in the human brain in vivo by means of double quantum coherence filtering. Magn. Reson. Med. 1999; 42: 283-289.
114. Hillered L, Valtysson J, Enblad P, Persson L. Interstitial glycerol as a marker for membrane phospholipid degradation in the acutely injured human brain. J. Neurol. Neurosurg. Psychiat. 1998; 64: 486-491.
115. Michaelis T, Helms G, Frahm J. Metabolic alterations in brain autopsies: proton NMR identification of free glycerol. NMR Biomed. 1996; 9: 121-124.
116. Kinoshita Y, Kajiwara H, Yokota A, Koga Y. Proton magnetic resonance spectroscopy of brain tumors: an in vitro study. Neurosurgery 1994; 35: 606-613. [Discussion 613-641].
117. Heindel W, Kugel H, Roth B. Noninvasive detection of increased glycine content by proton MR spectroscopy in the brains of two infants with nonketotic hyperglycinemia. AJNR 1993; 14: 629-635.
118. Schwartz JC, Lampart C, Rose C. Histamine formation in rat brain in vivo: effects of histidine loads. J. Neurochem. 1972; 19: 801-810.
119. 1H NMR. Magn. Reson. Med. 1986; 3: 150-156.
120. Vermathen P, Capizzano A, Laxer KD, Matson GB, Maudsley AA. Enhancement of histidine detection in vivo. A new approach for measuring brain pH. Proceedings of the International Society for Magnetic Resonance in Medicine, Abstract, 1999; p. 640.
121. Fogel WA, Andrzejewski W, Maslinski C. Neurotransmitters in hepatic encephalopathy. Acta Neurobiol. Exp. (Warsz.) 1990; 50: 281-293.
122. Fogel WA, Andrzejewski W, Maslinslci C. Brain histamine in rats with hepatic encephalopathy. J. Neurochem. 1991; 56: 38-43.
123. Scriver CR. ed. The Metabolic and Molecular Bases of Inherited Disease, McGraw-Hill, New York 1995.
124. 1H MRS detection of histidine in human brain: application to in vivo pH measurement. Magn. Reson. Med. 2000; 45: 665-675.
125. Pisano JJ, Wilson JD, Cohen L, Abraham D, Udenfriend S. Isolation of gamma aminobutyrylhistidine (homocarnosine) from brain. J. Biol. Chem. 1961; 236: 499-502.
126. Abraham D, Pisano JJ, Udenfriend S. The distribution of homocarnosine in mammals. Arch. Biochem. Biophys. 1962; 99: 210-213.
127. Kish SJ, Perry TL, Hansen S. Regional distribution of homocarnosine, homocarnosine-carnosine synthetase and homocarnosinase in human brain. J. Neurochem. 1979; 32: 1629-1636.
128. Perry TL, Kish SJ, Sjaastad O, Gjessing LR, Nesbakken R, Schrader H, Løken AC. Homocarnos inosis: increased content of homocarnosine and deficiency of homocarnosinase in brain. J. Neurochem. 1979; 32: 1637-1640.
129. Perry TL, Hansen S, Gandham SS. Postmortem changes of amino compounds in human and rat brain. J. Neurochem. 1981 ; 36: 406-410.
130. Gjessing LR, Lunde HA, Mrkrid L, Lenney JF, Sjaastad O. Inborn errors of carnosine and homocarnosine metabolism. J. Neural Transm. (Suppl.) 1990; 29: 91-106.
131. Rothman DL, Behar KL, Prichard JW, Petroff OA. Homocarnosine and the measurement of neuional pH in patients with epilepsy. Magn. Reson. Med. 1997; 38: 924-929.
132. Dictionary of Organic Compounds, Chapman and Hall, New York 1982.
133. Brand A, Richter-Landsberg C, Leibfritz D. Multinuclear NMR studies on the energy metabolism of glial and neuronal cells. Devl. Neurosci. 1993; 15: 289-298.
134. Shonk TK, Moats RA, Gifford P, Michaelis T, Mandigo JC, Izumi J, Ross BD. Probable Alzheimer disease: diagnosis with proton MR spectroscopy. Radiology 1995; 195: 65-72.
135. Moats RA, Ernst T, Shonk TK, Ross BD. Abnormal cerebral metabolite concentrations in patients with probable Alzheimer disease. Magn. Reson. Med. 1994; 32: 110-115.
136. Ross BD, Ernst T, Kreis R, Haseler LJ, Bayer S, Danielsen E, Blüml S, Shonk T, Mandigo JC, Caton W, Clark C, Jensen SW, Lehman NL, Arcinue E, Pudenz R, Shelden CH. 1H MRS in acute traumatic brain injury. J. Magn. Reson. Imag. 1998; 8: 829-840.
137. Michaelis T, Helms G, Merboldt KD, Hänicke W, Bruhn H, Frahm J. Identification of scyllo-inositol in proton NMR spectra of human brain in vivo. NMR Biomed. 1993; 6: 105-109.
138. Seaquist ER, Gruetter R. Identification of a high concentration of scyllo-inositol in the brain of a healthy human subject using 1H-and 13C-NMR. Magn. Reson. Med. 1998; 39: 313-316.
139. Michaelis T, Frahm J. On the 3.35 ppm singlet resonance in proton NMR spectra of brain tissue: scyllo-inositol or methanol contamination? Magn. Reson. Med. 1995; 34: 775-776.
140. Veech RL. The metabolism of lactate. NMR Biomed, 1991; 4: 53-58.
141. Sappey-Marinier D, Calabrese G, Fein G, Hugg JW, Biggins C, Weiner MW. Effect of photic stimulation on human visual cortex, lactate and phosphates using 1H and 31P magnetic resonance spectroscopy. J. Cereb. Blood Flow Metab. 1992; 12: 584-592.
142. Posse S, Dager SR, Richards TL, Yuan C, Ogg R, Artru AA, Müller-Gärtner HW, Hayes C. In vivo measurement of regional brain metabolic response to hyperventilation using magnetic resonance: proton echo planar spectroscopic imaging PEPSI. Magn. Reson. Med. 1997; 37: 858-865.
143. Hurd RE, Freeman D. Proton editing and imaging of lactate. NMR Biomed. 1991; 4: 73-80.
144. Novotny EJ, Avison MJ, Herschkowitz N, Petroff OA, Prichard JW, Seashore MR, Rothman DL. In vivo measurement of phenylalanine in human brain by proton nuclear magnetic resonance spectroscopy. Pediatr. Res. 1995; 37: 244-249.
145. StryerL. Biochemistry, W. H. Freeman, San Francisco, CA 1981.
146. Bick U, Ullrich K, Stöber U, Möller HE, Schuierer G, Ludolph AC, Oberwittler C, Weglage J, Wendel U. White matter abnormalities in patients with treated hyperphenylalaninaemia: magnetic resonance relax ometry and proton spectroscopy findings. Eur. J. Pediatr. 1993; 152: 1012-1020.
147. Pietz J, Kreis R, Boesch C, Penzien J, Rating D, Herschkowitz N. The dynamics of brain concentrations of phenylalanine and its clinical significance in patients with phenylketonuria determined by in vivo 1H magnetic resonance spectroscopy. Pediatr. Res. 1995; 38: 657-663.
148. Kreis R, Pietz J, Penzien J, Herschkowitz N, Boesch C. Identification and quantitation of phenylalanine in the brain of patients with phenylketonuria by means of localized in vivo 1H magnetic-resonance spectroscopy. J. Magn. Reson. Ser. B 1995; 107: 242-251.
149. Möller HE, Vermathen P, Ullrich K, Weglage J, Koch HG, Peters PE. In vivo NMR spectroscopy in patients with phenylketonuria: changes of cerebral phenylalanine levels under dietary treatment. Neuropediatrics 1995; 26: 199-202.
150. Pietz J, Kreis R, Schmidt H, Meyding-Lamadé UK, Rupp A, Boesch C. Phenylketonuria: findings at MR imaging and localized in vivo H-1 MR spectroscopy of the brain in patients with early treatment. Radiology 1996; 201: 413-420.
151. Möller HE, Weglage J, Wiedermann D, Vermathen P, Bick U, Ullrich K. Kinetics of phenylalanine transport at the human blood-brain barrier investigated in vivo. Brain Res. 1997; 778: 329-337.
152. Möller HE, Weglage J, Wiedermann D, Ullrich K. Blood-brain barrier phenylalanine transport and individual vulnerability in phenylketonuria. J. Cereb. Blood Flow Metab. 1998; 18: 1184-1191.
153. Kohli A, Gupta RK, Poptani H, Roy R. In vivo proton magnetic resonance spectroscopy in a case of intracranial hydatid cyst. Neurology 1995; 45: 562-564.
154. Hardy DL, Norwood TJ. Spectral editing techniques for the in vitro and in vivo detection of taurine. J. Magn. Reson. 1998; 133: 70-78.
155. Roser W, Duc CO, Steinbrich W, Radue EW. Dangerous increase of taurine in the human brain after consumption of an 'energy drink'. Proceedings of the International Society for Magnetic Resonance in Medicine. Abstract, 1998 p. 1886.
156. Young SN. Behavioral effects of dietary neurotransrnitter precursors: basic and clinical aspects. Neurosci. Biobehav. Rev. 1996; 20: 313-323.
157. Haseler LJ, Sibbitt WJ, Sibbitt RR, Hart BL. Neurologic, MR imaging, and MR spectroscopic findings in eosinophilia myalgia syndrome. AJNR 1998; 19: 1687-1694.
158. al Mardini H, Harrison EJ, Ince PG, Bartlett K, Record CO. Brain indoles in human hepatic encephalopathy. Hepatology 1993; 17: 1033-1040.
159. Acworth IN, During MJ, Wurtman RJ. Processes that couple amino acid availability to neurotransrnitter synthesis and release. In Amino Acid Availability and Brain Function in Health and Disease, G. Huether, Eds., pp. 117-136, Springer, Berlin (1987).
160. de Graaf RA, van Kranenburg A, Nicolay K. Off-resonance metabolite magnetization transfer measurements on rat brain in situ. Magn. Reson. Med. 1999; 41: 1136-1144.
161. van Zijl PC, Barker PB. Magnetic resonance spectroscopy and spectroscopic imaging for the study of brain metabolism. Ann. NY Acad. Sci. 1997; 820: 75-96.
162. Siegel GJ, Agranoff BW, Albers RW, Molinoff P. Basic Neurochemistry: Molecular, Cellular, and Medical Aspects, Raven Press, New York (1989).
163. Perry TL, Hansen S, Berry K, Mok C, Lesk D. Free amino acids and related compounds in biopsies of human brain. J. Neurochem. 1971; 18: 521-528.